|
|
|
|
|
| Available: 0 |
| List Price:$319.00 |
|
Other formats:
|
| Edition: | 1st |
| Publisher: | Springer Nature |
| ISBN: | 0-387-69257-6 (0387692576) |
| ISBN-13: | 978-0-387-69257-9 (9780387692579) |
| Binding: | Hardcover |
| Copyright: | 2010 |
| Publish Date: | 01/10 |
| Volume: | 145 |
| Weight: | 1.21 Lbs. |
| Pages: | 280 |
| Subject Class: | ONC (Oncology) |
| Remarks: | Print on Demand. Please allow additional time for delivery. |
| Return Policy: | Returns accepted up to 12 months provided no other recalls or return restrictions apply. |
| Table Of Contents: |
View
|
| Contributing Authors: |
View
|
| ProQuest Ebook Central: |
Available in ProQuest Ebook Central™ View
|
|
|
| |
| ISSN Series: | Cancer Treatment and Research | | Discipline: | Hematology | | Subject Definition: | Leukemia, Myeloid, Acute | | NLM Class: | WH 250 | | LC Class: | RC643 | | Abstract: | Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered. |
|
|
|
|
|
|
Follow Matthews Book Co. on:
Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews